With no FluMist, CDC worries flu vaccination rates could slip

About 20 million people and one-third of children in the U.S. received AstraZeneca’s FluMist last year to protect against the seasonal virus, health officials told reporters during a press conference. And with the nasal mist no longer an option this year, the CDC is concerned that vaccination rates could suffer.

Canadian study finds AZ's FluMist effective

Following the June decision by a CDC committee to recommend against any use of AstraZeneca’s FluMist Quadrivalent for the upcoming flu season, a Canadian study published this week found the trivalent version of the vaccine was as effective as an inactivated flu shot over three seasons.